“We’ve already made, actually, billions of doses preparing for the launch,” Chief Executive Officer
Lilly hasn’t yet submitted the pill, called orforglipron, to US regulators but expects to do so before the end of the year. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
